The Supreme Court determined to ban most non-consensual third-party releases in Chapter 11 plans, rejecting the Second Circuit’s seven-part multifactor analysis for considering such releases and sending the Purdue plan back to the lower courts. https://bit.ly/4csImOs #supremecourt #bankruptcycode #pharma
Choate, Hall & Stewart LLP’s Post
More Relevant Posts
-
ICYMI: Over the weekend, we had Yetter Coleman LLP partner Matthew Zorn on The Dales Report to help us break down a recently released government drug policy document. 👉 How did this once-confidential report make its way into public hands? 👉 What does it say about cannabis and the DEA's stance on it? 👉 What implications could this have on US drug policy going forward? All this and more at the link in the comments. #cannabislaw #drugpolicy #cannabisreform
To view or add a comment, sign in
-
For the first time, the Biden Administration is proposing a framework to consider drug prices when deciding on march-in rights under the Bayh-Dole Act. This is sure to generate much debate and litigation. Stay tuned for updates! #BidenAdministration #DrugPricing #BayhDoleAct
To view or add a comment, sign in
-
It has been a busy year for issues related to drug pricing, and with the election around the corner, litigation issues that have been developing over the last few years are likely to be a key focus for the second half of 2024. The White & Case team analyzes these developments and their implications for the industry in their latest alert. https://ow.ly/fpy550SSfgn #whitecase
Three Drug Pricing Litigation Issues to Watch in the Second Half of 2024 | White & Case LLP
whitecase.com
To view or add a comment, sign in
-
It has been a busy year for issues related to drug pricing, and with the election around the corner, litigation issues that have been developing over the last few years are likely to be a key focus for the second half of 2024. The White & Case team analyzes these developments and their implications for the industry in their latest alert. https://ow.ly/LtLx50STfFb #whitecase
Three Drug Pricing Litigation Issues to Watch in the Second Half of 2024 | White & Case LLP
whitecase.com
To view or add a comment, sign in
-
It has been a busy year for issues related to drug pricing, and with the election around the corner, litigation issues that have been developing over the last few years are likely to be a key focus for the second half of 2024. The White & Case team analyzes these developments and their implications for the industry in their latest alert. https://ow.ly/jWIW50SSiMj #whitecase
Three Drug Pricing Litigation Issues to Watch in the Second Half of 2024 | White & Case LLP
whitecase.com
To view or add a comment, sign in
-
It has been a busy year for issues related to drug pricing, and with the election around the corner, litigation issues that have been developing over the last few years are likely to be a key focus for the second half of 2024. The White & Case team analyzes these developments and their implications for the industry in their latest alert. https://ow.ly/FKhC50SThXH #whitecase
Three Drug Pricing Litigation Issues to Watch in the Second Half of 2024 | White & Case LLP
whitecase.com
To view or add a comment, sign in
-
It has been a busy year for issues related to drug pricing, and with the election around the corner, litigation issues that have been developing over the last few years are likely to be a key focus for the second half of 2024. The White & Case team analyzes these developments and their implications for the industry in their latest alert. https://ow.ly/C0lS50SSlPu #whitecase
Three Drug Pricing Litigation Issues to Watch in the Second Half of 2024 | White & Case LLP
whitecase.com
To view or add a comment, sign in
-
It has been a busy year for issues related to drug pricing, and with the election around the corner, litigation issues that have been developing over the last few years are likely to be a key focus for the second half of 2024. The White & Case team analyzes these developments and their implications for the industry in their latest alert. https://ow.ly/BqWA50SSf2c #whitecase
Three Drug Pricing Litigation Issues to Watch in the Second Half of 2024 | White & Case LLP
whitecase.com
To view or add a comment, sign in
-
It has been a busy year for issues related to drug pricing, and with the election around the corner, litigation issues that have been developing over the last few years are likely to be a key focus for the second half of 2024. The White & Case team analyzes these developments and their implications for the industry in their latest alert. https://ow.ly/Qm9E50STHL2 #whitecase
Three Drug Pricing Litigation Issues to Watch in the Second Half of 2024 | White & Case LLP
whitecase.com
To view or add a comment, sign in
-
Learn about jurisdiction regarding federal vs state drug charges.
Federal vs. State Drug Charges: Understanding Jurisdiction in Nashville - Blog
To view or add a comment, sign in